USA - New York Stock Exchange - NYSE:MDT - IE00BTN1Y115 - Common Stock
The current stock price of MDT is 97.53 USD. In the past month the price decreased by -3.22%. In the past year, price increased by 20.92%.
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABT | ABBOTT LABORATORIES | 25.23 | 218.96B | ||
| ISRG | INTUITIVE SURGICAL INC | 68.09 | 207.82B | ||
| BSX | BOSTON SCIENTIFIC CORP | 33.1 | 144.75B | ||
| SYK | STRYKER CORP | 27.91 | 140.55B | ||
| BDX | BECTON DICKINSON AND CO | 14.06 | 57.87B | ||
| IDXX | IDEXX LABORATORIES INC | 56.57 | 56.96B | ||
| EW | EDWARDS LIFESCIENCES CORP | 33.12 | 49.40B | ||
| GEHC | GE HEALTHCARE TECHNOLOGY | 19.02 | 39.76B | ||
| RMD | RESMED INC | 25.5 | 36.85B | ||
| DXCM | DEXCOM INC | 36.24 | 26.29B | ||
| PODD | INSULET CORP | 63.25 | 20.33B | ||
| ZBH | ZIMMER BIOMET HOLDINGS INC | 11.48 | 18.40B |
Medtronic Plc is a medical technology company, which engages in the development, manufacture, distribution, and sale of device-based medical therapies and services. The company is headquartered in Galway, Connacht and currently employs 95,000 full-time employees. The Company’s products category includes Advanced Surgical Technology; Cardiac Rhythm; Cardiovascular; Digestive & Gastrointestinal; Ear, Nose & Throat; General Surgery; Gynecological; Neurological; Oral & Maxillofacial; Patient Monitoring; Renal Care; Respiratory; Spinal & Orthopedic; Surgical Navigation & Imaging; Urological; Product Manuals; Product Ordering & Inquiries; and Product Performance & Advisories. Its products include Cardiac Implantable Electronic Device (CIED) Stabilization, Aortic Stent Graft Products, CareLink Personal Therapy Management Software, CareLink Pro Therapy Management Software. Its services and solutions include Ambulatory Surgery Center Resources, Care Management Services, Digital Connectivity Information Technology (IT) Support, Equipment Services and Support, Innovation Lab, Medtronic Healthcare Consulting, and Office-Based Sinus Surgery.
MEDTRONIC PLC
Building Two Parkmore Business Park West
GALWAY CONNACHT D02 IE
CEO: Geoffrey S. Martha
Employees: 95000
Phone: 35314381700
Medtronic Plc is a medical technology company, which engages in the development, manufacture, distribution, and sale of device-based medical therapies and services. The company is headquartered in Galway, Connacht and currently employs 95,000 full-time employees. The Company’s products category includes Advanced Surgical Technology; Cardiac Rhythm; Cardiovascular; Digestive & Gastrointestinal; Ear, Nose & Throat; General Surgery; Gynecological; Neurological; Oral & Maxillofacial; Patient Monitoring; Renal Care; Respiratory; Spinal & Orthopedic; Surgical Navigation & Imaging; Urological; Product Manuals; Product Ordering & Inquiries; and Product Performance & Advisories. Its products include Cardiac Implantable Electronic Device (CIED) Stabilization, Aortic Stent Graft Products, CareLink Personal Therapy Management Software, CareLink Pro Therapy Management Software. Its services and solutions include Ambulatory Surgery Center Resources, Care Management Services, Digital Connectivity Information Technology (IT) Support, Equipment Services and Support, Innovation Lab, Medtronic Healthcare Consulting, and Office-Based Sinus Surgery.
The current stock price of MDT is 97.53 USD. The price decreased by -1.18% in the last trading session.
MEDTRONIC PLC (MDT) has a dividend yield of 2.96%. The yearly dividend amount is currently 2.77.
MDT has a ChartMill Technical rating of 5 out of 10 and a ChartMill Fundamental rating of 6 out of 10.
39 analysts have analysed MDT and the average price target is 112.26 USD. This implies a price increase of 15.1% is expected in the next year compared to the current price of 97.53.
MEDTRONIC PLC (MDT) will report earnings on 2026-02-17, before the market open.
The outstanding short interest for MEDTRONIC PLC (MDT) is 1.18% of its float.
ChartMill assigns a technical rating of 5 / 10 to MDT. When comparing the yearly performance of all stocks, MDT turns out to be only a medium performer in the overall market: it outperformed 65.02% of all stocks.
ChartMill assigns a fundamental rating of 6 / 10 to MDT. MDT has an excellent profitability rating, but there are some minor concerns on its financial health.
Over the last trailing twelve months MDT reported a non-GAAP Earnings per Share(EPS) of 5.63. The EPS increased by 7.24% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 13.71% | ||
| ROA | 5.22% | ||
| ROE | 9.79% | ||
| Debt/Equity | 0.57 |
39 analysts have analysed MDT and the average price target is 112.26 USD. This implies a price increase of 15.1% is expected in the next year compared to the current price of 97.53.
For the next year, analysts expect an EPS growth of 3.64% and a revenue growth 7.65% for MDT